Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2018

Apr 3, 2018

33148_dirs_2018-04-02_288ddf4e-6f91-4065-9082-9de26bc9b75f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2018-03-29

Reporting Person: Patel Kinnari (Chief Operating Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-03-29 Stock Option (Right to Buy) $18.75 A 175000 Acquired 2028-03-29 Common Stock (175000) Direct

Footnotes

F1: This option represents a right to purchase a total of 175,000 shares of the Issuer's Common Stock, 58,336 of which will become fully vested and exercisable on March 29, 2019, with the remaining 116,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.